Clinical Trial Update: Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update showing major pathologic response (ycT0-1) after neoadjuvant chemoradiotherapy with local excision for clinical T3 rectal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN